ESTRELLA IMMUNOPHARMA, INC. Proceeds from Related Party Debt
ESTRELLA IMMUNOPHARMA, INC. (ESLA) reported Proceeds from Related Party Debt of $273.07 thousand for the 6-month period ending 2023-06-30, per its 10-Q filed 2023-08-01.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromRelatedPartyDebt · last filed 2023-08-01
- ESTRELLA IMMUNOPHARMA, INC. proceeds from related party debt for the quarter ending 2023-06-30 was $136.53K.
- ESTRELLA IMMUNOPHARMA, INC. proceeds from related party debt for the quarter ending 2023-03-31 was $136.53K.
- ESTRELLA IMMUNOPHARMA, INC. proceeds from related party debt for the quarter ending 2022-12-31 was -$498.60K.
- ESTRELLA IMMUNOPHARMA, INC. proceeds from related party debt for the quarter ending 2021-12-31 was $0.00.
- ESTRELLA IMMUNOPHARMA, INC. proceeds from related party debt for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
- ESTRELLA IMMUNOPHARMA, INC. proceeds from related party debt for fiscal 2021 was $300.00K.
| Period end | Proceeds from Related Party Debt 3 month | Proceeds from Related Party Debt 6 month | Proceeds from Related Party Debt 9 month | Proceeds from Related Party Debt 12 month |
|---|---|---|---|---|
| 2023-06-30 | $136.53K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-01 | $273.07K 10-Q · filed 2023-08-01 | -$225.53K derived: sum of 3 quarters · filed 2023-08-01 | |
| 2023-03-31 | $136.53K 10-Q · filed 2023-05-18 | -$362.07K derived: sum of 2 quarters · filed 2023-05-18 | ||
| 2022-12-31 | -$498.60K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-14 | $0.00 10-K · filed 2023-03-14 | ||
| 2022-09-30 | $498.60K 10-Q · filed 2022-11-14 | |||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-14 | $0.00 derived: sum of 2 quarters · filed 2023-03-14 | $100.00K derived: sum of 3 quarters · filed 2023-03-14 | $300.00K 10-K · filed 2023-03-14 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $100.00K derived: sum of 2 quarters · filed 2022-11-14 | $300.00K 10-Q · filed 2022-11-14 | |
| 2021-06-30 | $100.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $300.00K 10-Q · filed 2022-08-08 | ||
| 2021-03-31 | $200.00K 10-Q · filed 2022-05-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |